As summarized in a later section, medicines based on glucagon-like peptide-1 (GLP-1) are available for weight management in people with overweight or obesity and for the management of T2D, and evidence suggests potential kidney-protective benefits as well. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.